You are viewing the site in preview mode

Skip to main content

Table 3 Incidence rates of health outcomes of interest among advanced stage ovarian cancer patients

From: A real-world study on characteristics, treatments and outcomes in US patients with advanced stage ovarian cancer

Health outcome of interest After advanced stage date (n=12,659) After anti-cancer therapy date (n=7,723)
Events Person-years IRa 95% CI Events Person-years IR 95% CI
Serious infectionb 6662 25868 25.78 25.17 26.41 5,862 15938 41.42 40.36 42.49
Rash
 Any rash 686 22684 3.02 2.8 3.26 431 14095 3.06 2.78 3.36
 Severe cutaneous rash safety events 87 25534 0.34 0.27 0.42 62 15752 0.39 0.3 0.5
Colitis 725 23251 3.12 2.9 3.35 464 14567 3.19 2.91 3.49
Pneumonitis
 Interstitial lung disease 119 25622 0.46 0.39 0.55 62 15812 0.39 0.3 0.5
 Hypersensitivity pneumonitis ≤10 n/a 0.03 0.02 0.06 ≤10 n/a 0.03 0.01 0.06
 Pneumonitis or acute interstitial pneumonitis 137 25653 0.53 0.45 0.63 83 15824 0.52 0.42 0.65
Hepatitis
 Hepatic failure 764 23057 3.31 3.08 3.55 510 14112 3.61 3.31 3.94
 Autoimmune hepatitis ≤10 n/a 0.02 0.01 0.05 ≤10 n/a 0.03 0.01 0.07
 Hepatitis (not specified as viral) 66 25559 0.26 0.2 0.33 23 15798 0.15 0.09 0.21
 Liver disorder 1439 21567 6.67 6.33 7.02 960 13128 7.31 6.86 7.79
 Transaminases increased 272 25086 1.08 0.96 1.22 169 15483 1.09 0.94 1.27
Nephritis 1966 21201 9.27 8.87 9.69 1,309 13361 9.80 9.28 10.34
Renal failure 2057 21425 9.60 9.19 10.02 1,379 13524 10.20 9.67 10.75
Endocrinopathies
 Adrenal insufficiency 87 25608 0.34 0.27 0.42 44 15839 0.28 0.2 0.37
 Acute and chronic thyroiditis 88 25310 0.35 0.28 0.43 45 15665 0.29 0.21 0.38
 Diabetes mellitus, type 1 124 24894 0.50 0.42 0.59 65 15482 0.42 0.33 0.53
 Diabetic ketoacidosis 40 25745 0.16 0.11 0.21 20 15891 0.13 0.08 0.19
 Hypogonadism ≤10 n/a 0.02 0.01 0.05 ≤10 n/a 0.01 0 0.03
 Hypophysitis or hypopituitarism 90 25653 0.35 0.28 0.43 49 15826 0.31 0.23 0.41
 Hypothyroidism 636 18796 3.38 3.13 3.65 325 12002 2.71 2.43 3.01
 Thyroid hyperfunction disorders 121 25084 0.48 0.4 0.57 59 15554 0.38 0.29 0.49
Other safety events
 Abdominal pain 1825 5206 35.06 33.48 36.69 859 3098 27.73 25.92 29.63
 Anemia 2925 11827 24.73 23.85 25.64 1,978 7576 26.11 24.98 27.28
 Anorexia 649 24889 2.61 2.41 2.81 469 15316 3.06 2.79 3.35
 Autoimmune disorder 182 25347 0.72 0.62 0.83 135 15657 0.86 0.73 1.02
 Backache 1632 20754 7.86 7.49 8.25 963 13124 7.34 6.89 7.81
 Constipation 2086 18379 11.35 10.87 11.85 1,404 11460 12.25 11.62 12.91
 Cough 1421 19219 7.39 7.02 7.79 848 12341 6.87 6.42 7.35
 Diarrhea 1502 20365 7.38 7.01 7.76 1,028 12630 8.14 7.65 8.65
 Disorders of bilirubin excretion 66 25798 0.26 0.2 0.32 52 15904 0.33 0.25 0.43
 Disorders of phosphorus metabolism 294 25265 1.16 1.04 1.3 177 15637 1.13 0.97 1.31
 Dizziness and giddiness 977 21121 4.63 4.34 4.92 604 13504 4.47 4.13 4.84
 Edema 1773 20466 8.66 8.27 9.07 1,107 12978 8.53 8.04 9.04
 Encephalitis 18 25811 0.07 0.04 0.11 13 15904 0.08 0.05 0.14
 Fever 1848 20676 8.94 8.54 9.35 1,313 12860 10.21 9.67 10.77
 Guillain-Barre Syndrome ≤10 n/a 0.02 0.01 0.05 ≤10 n/a 0.03 0.01 0.06
 Hypertension 1243 10422 11.93 11.28 12.6 775 6820 11.36 10.58 12.18
 Hypopotassemia 1808 20815 8.69 8.29 9.09 1,211 12983 9.33 8.81 9.86
 Hyposmolality and/or hyponatremia 1475 23036 6.40 6.08 6.74 965 14302 6.75 6.33 7.18
 Hypoxemia 1034 23624 4.38 4.12 4.65 590 14805 3.99 3.67 4.32
 Iritis 36 25653 0.14 0.1 0.19 13 15839 0.08 0.05 0.14
 Leukocytosis 1280 23275 5.50 5.2 5.81 792 14379 5.51 5.13 5.9
 Localized superficial swelling, mass, or lump 385 25036 1.54 1.39 1.7 240 15436 1.55 1.37 1.76
 Lymphocytopenia 17 25841 0.07 0.04 0.1 12 15926 0.08 0.04 0.13
 Malaise and fatigue 2945 14296 20.60 19.87 21.35 2,089 9143 22.85 21.88 23.84
 Myasthenia gravis ≤10 n/a 0.03 0.01 0.05 ≤10 n/a 0.02 0.01 0.05
 Myocarditis ≤10 n/a 0.01 0 0.02 ≤10 n/a 0.01 0 0.04
 Myositis 352 22731 1.55 1.39 1.72 192 14275 1.34 1.16 1.55
 Nausea and vomiting 3436 13816 24.87 24.05 25.71 2,615 8033 32.55 31.32 33.82
 Pain in joint 1584 14017 11.30 10.75 11.87 930 9254 10.05 9.42 10.71
 Pain in limb 1741 16749 10.39 9.91 10.89 1,048 10874 9.64 9.07 10.24
 Pancreatitis (acute or autoimmune) 146 25386 0.58 0.49 0.67 82 15678 0.52 0.42 0.65
 Psoriasis 59 25370 0.23 0.18 0.3 30 15634 0.19 0.13 0.27
 Respiratory abnormalities ≤10 n/a 0.01 0 0.02 ≤10 n/a 0.01 0 0.03
 Rheumatoid Arthritis 130 24912 0.52 0.44 0.62 70 15387 0.45 0.36 0.57
 Sarcoidosis 32 25689 0.12 0.09 0.17 ≤10 n/a 0.06 0.03 0.1
 Systemic inflammatory response syndrome 116 25634 0.45 0.38 0.54 82 15789 0.52 0.42 0.64
 Thrombocytopenia 1389 23210 5.98 5.68 6.31 1,181 13985 8.44 7.97 8.94
 Uveitis ≤10 n/a 0.00 0 0.02 0 15938 0.00 0 0.02
 Vitiligo ≤10 n/a 0.03 0.01 0.05 ≤10 n/a 0.04 0.02 0.08
Overall Mortality 3051 18414 16.57 15.99 17.16 1903 8731 21.80 20.83 22.79
  1. Abbreviations: CI Confidence interval, IR Incidence rate
  2. aEstimates of IR are shown per 100 person-years. Incidence is calculated as the number of new events divided by the sum of person-time at risk, defined as the time between the start of follow-up and the date of the event. In each row, individuals who had a diagnosis of the applicable event prior to the start of follow-up (i.e., prevalent cases) were not included.
  3. bBecause serious infections were defined based on the need for acute care, all events occurred in hospital or emergency room settings.
Back to article page

Journal of Ovarian Research

ISSN: 1757-2215

Contact us